Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions

06/10/2022
by   Kaspar Rufibach, et al.
0

For the analysis of a time-to-event endpoint in a single-arm or randomized clinical trial it is generally perceived that interpretation of a given estimate of the survival function, or the comparison between two groups, hinges on some quantification of the amount of follow-up. Typically, a median of some loosely defined quantity is reported. However, whatever median is reported, is typically not answering the question(s) trialists actually have in terms of follow-up quantification. In this paper, inspired by the estimand framework, we formulate a comprehensive list of relevant scientific questions that trialists have when reporting time-to-event data. We illustrate how these questions should be answered, and that reference to an unclearly defined follow-up quantity is not needed at all. In drug development, key decisions are made based on randomized controlled trials, and we therefore also discuss relevant scientific questions not only when looking at a time-to-event endpoint in one group, but also for comparisons. We find that with the advent of new therapies, patterns of survival functions in trials emerge, e.g. delayed separation in RCTs or the potential for cure, that may require different thinking on some of the relevant scientific questions around follow-up. We conclude the paper with practical recommendations.

READ FULL TEXT
research
11/20/2017

Treatment Effect Quantification for Time-to-event Endpoints -- Estimands, Analysis Strategies, and beyond

A draft addendum to ICH E9 has been released for public consultation in ...
research
12/21/2022

Duration of and time to response in oncology clinical trials from the perspective of the estimand framework

Duration of response (DOR) and time to response (TTR) are typically eval...
research
10/01/2020

Estimands in Hematologic Oncology Trials

The estimand framework included in the addendum to the ICH E9 guideline ...
research
08/18/2020

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) – estimation of adverse event risks

The SAVVY project aims to improve the analyses of adverse event (AE) dat...
research
12/15/2020

Effect of right censoring bias on survival analysis

Kaplan-Meier survival analysis represents the most objective measure of ...
research
06/01/2022

Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trial in Health Technology Assessment

Background Survival extrapolation is essential in the cost-effectiveness...
research
08/17/2019

Decline of COPD exacerbations in clinical trials over two decades – a systematic review and meta-regression

BACKGROUND: An important goal of chronic obstructive pulmonary disease (...

Please sign up or login with your details

Forgot password? Click here to reset